-
Opinions on the consequences of marijuana use are wide-ranging: Some experts express grave concern that it may induce COPD, increase risk of lung cancer, promote the emergence of schizophrenia, and lead to "heavy drug" use; others essentially dismiss these (potential) adversities as inadequately established to permit accusations that marijuana has any commonplace serious adverse effects.
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
Correlating the findings in the 13,331 adults 20 years or older in the Third National Health and Nutrition Examination Survey (NHANES III) revealed that vitamin D deficiency is a risk factor for developing cardiovascular disease and is associated with increased all-cause mortality.
-
The patient whose 12-lead ECG and rhythm strip is shown above had chest discomfort at the time this tracing was recorded. In light of this history, how do you interpret the tracing?
-
-
Zaman et al randomized 340 pregnant Bangladeshi women to receive either inactivated influenza or pneumococcal polysaccharide (control group) vaccine.
-
This interesting study just surfaced in the British Journal of Obstetrics and Gynecology that addressed the relationship between spastic cerebral palsy (CP) and asphyxia-related causes.
-
In the issue: 5-á reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
Older people who report memory decline or show objective evidence of cognitive impairment are more likely to develop Alzheimer's disease and other forms of dementia over time.
-
Miller and colleagues, representing 29 study centers in the United States, reported the results of a Phase 2 clinical trial, assessing the impact of denosumab on bone density.
